株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経因性疼痛:パイプライン製品の分析

Neuropathic Pain - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 232786
出版日 ページ情報 英文 838 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。
Back to Top
神経因性疼痛:パイプライン製品の分析 Neuropathic Pain - Pipeline Review, H2 2019
出版日: 2019年12月16日 ページ情報: 英文 838 Pages
概要

神経因性疼痛、あるいは神経痛は感覚システムが受けた状態を指し、一般的には組織障害を伴います。神経線維は損傷すると異常信号を発します。神経因性疼痛はそのほかの疾患と一緒に発生します。症侯は電撃痛から無感覚まであります。 痛みを起こす素因はいくつかあるものの、特定の原因はありません。身体的外傷、腎臓病、アルコール依存症、感染症、ストレスなどが痛みの症状につながることもあります。 治療は、薬物療法や心理療法で症状を和らげます。

当レポートでは、神経因性疼痛の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

神経因性疼痛の概要

治療薬の開発

神経因性疼痛:企業で開発中の治療薬

神経因性疼痛:大学/機関で研究中の治療薬

神経因性疼痛:パイプライン製品の概況

神経因性疼痛:企業で開発中の製品

神経因性疼痛:大学/機関で研究中の製品

神経因性疼痛の治療薬開発に従事している企業

神経因性疼痛:治療薬の評価

薬剤プロファイル

神経因性疼痛:休止中のプロジェクト

神経因性疼痛:開発が中止された製品

神経因性疼痛:製品開発のマイルストーン

付録

図表

List of Tables

  • Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Abalone Bio Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Achelios Therapeutics Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Acorda Therapeutics Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Adynxx Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AfaSci Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Affectis Pharmaceuticals AG, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Akelos Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Algomedix Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Alion Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Allergan Plc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Allodynic Therapeutics LLC, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AlphaNavi Pharma Co Ltd, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Amgen Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AnaBios Corp, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Anavex Life Sciences Corp, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Angelini Group, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AngioChem Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Anida Pharma Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AnyGen Co Ltd, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AOBiome LLC, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by APT Therapeutics Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Aptarion biotech AG, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Aptinyx Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Araim Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Artelo Biosciences Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Asahi Kasei Pharma Corp, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Asarina Pharma AB, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Astellas Pharma Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Astraea Therapeutics LLC, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AstraZeneca Plc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by AusCann Group Holdings Ltd, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
  • Neuropathic Pain (Neuralgia) - Pipeline by Avilex Pharma ApS, H2 2019

List of Figures

  • Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11588IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain (Neuralgia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 21, 46, 45, 1, 4, 157, 30 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 34 and 2 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Neuropathic Pain (Neuralgia) - Overview
  • Neuropathic Pain (Neuralgia) - Therapeutics Development
  • Neuropathic Pain (Neuralgia) - Therapeutics Assessment
  • Neuropathic Pain (Neuralgia) - Companies Involved in Therapeutics Development
  • Neuropathic Pain (Neuralgia) - Drug Profiles
  • Neuropathic Pain (Neuralgia) - Dormant Projects
  • Neuropathic Pain (Neuralgia) - Discontinued Products
  • Neuropathic Pain (Neuralgia) - Product Development Milestones
  • Appendix
Back to Top